Financial Performance - The company's revenue for Q1 2024 was ¥1,660,204,321.44, a decrease of 8.00% compared to ¥1,804,571,375.28 in the same period last year[5] - Net profit attributable to shareholders was ¥235,072,002.70, down 58.65% from ¥568,455,092.87 year-on-year[5] - The basic and diluted earnings per share decreased by 59.09% to ¥0.27 from ¥0.66 in the same period last year[5] - The net profit for Q1 2024 was CNY 312,570,373.39, a decrease of 45.0% compared to CNY 568,325,660.27 in Q1 2023[24] - The operating profit for Q1 2024 was CNY 362,196,228.41, a decline of 42.6% from CNY 630,897,782.90 in Q1 2023[24] - The company reported a total comprehensive income of CNY 290,331,159.48 for Q1 2024, down from CNY 521,771,775.19 in Q1 2023[24] - The total revenue from operating activities was CNY 1,476,940,313.67, down 3.2% from CNY 1,525,588,216.35 in the previous year[26] Cash Flow - The net cash flow from operating activities increased significantly by 405.83%, reaching ¥144,204,460.07 compared to ¥28,508,219.40 in the previous year[9] - The cash flow from operating activities generated a net amount of CNY 144,204,460.07, significantly up from CNY 28,508,219.40 in the same period last year[26] - The cash flow from investing activities showed a net outflow of CNY 119,716,564.11, an improvement from a net outflow of CNY 547,512,821.57 in the previous year[26] - The cash flow from financing activities generated a net inflow of CNY 2,424,771.97, a significant decrease from CNY 302,161,242.23 in Q1 2023[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥30,070,185,491.17, reflecting a 1.31% increase from ¥29,680,742,349.17 at the end of the previous year[5] - The total assets as of March 31, 2024, amounted to CNY 30,070,185,491.17, up from CNY 29,680,742,349.17 at the beginning of the year[22] - The total liabilities increased to CNY 5,536,893,616.67 from CNY 5,227,180,203.91, indicating a rise in financial obligations[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,740[11] - The largest shareholder, Ye Xiaoping, holds 20.49% of shares, totaling 177,239,541 shares[11] - The second largest shareholder, HKSCC NOMINEES LIMITED, holds 14.23% of shares, totaling 123,116,179 shares[11] - The top 10 shareholders account for a significant portion of the company's equity, with the top three alone holding over 40%[11] - The company has no preferred shareholders as indicated by the absence of any in the report[16] Investment and Income - The company reported a significant decrease in investment income, down 113.93% to -¥3,591,151.18 from ¥25,784,682.29 year-on-year[8] - The fair value change income dropped by 92.77% to ¥12,753,272.78 compared to ¥176,412,728.63 in the previous year, primarily due to a decline in the stock prices of other non-current financial assets[8] - The company received government subsidies amounting to ¥12,209,543.65 during the reporting period, contributing to an increase in other income by 198.25%[8] Cost Management - Total operating costs for Q1 2024 were CNY 1,305,287,804.37, down from CNY 1,360,291,377.24, reflecting a cost reduction strategy[23] - Research and development expenses for Q1 2024 were CNY 63,906,152.52, slightly down from CNY 64,519,361.97, indicating a focus on cost management in R&D[23] Equity and Share Restrictions - The company’s equity attributable to shareholders increased to CNY 21,131,829,587.05 from CNY 21,026,774,725.75, reflecting a positive trend in shareholder value[22] - The total number of restricted shares held by Ye Xiaoping is 132,929,656, which is subject to a 25% annual release[17] - The total number of restricted shares held by Cao Xiaochun is 38,746,330, also subject to a 25% annual release[17] - The company has a total of 171,687,044 restricted shares across all shareholders[17] - There were no changes in the number of restricted shares during the reporting period[17] - The report indicates no participation in margin financing by the top shareholders[12] Future Outlook - The company plans to continue exploring market expansion opportunities and new product development as part of its growth strategy[19]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,660,204,321.44, representing a decrease of 8.00% compared to the same period last year[10]. - Net profit attributable to shareholders for Q1 2024 was CNY 235,072,002.70, down 58.65% year-on-year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 303,052,196.14, a decrease of 20.50% compared to the previous year[10]. - Basic earnings per share for Q1 2024 were CNY 0.27, down 59.09% year-on-year[10]. - Operating profit for the current period was ¥362,196,228.41, a decline of 42.67% compared to ¥630,897,782.90 in the previous period[46]. - Net profit for the current period was ¥312,570,373.39, down 45.03% from ¥568,325,660.27 in the previous period[46]. - Total comprehensive income for the current period was ¥290,331,159.48, down 44.24% from ¥521,771,775.19 in the previous period[48]. - The company reported a decrease in investment income, recording a loss of ¥3,591,151.18 compared to a gain of ¥25,784,682.29 in the previous period[45]. Cash Flow - The net cash flow from operating activities increased significantly to CNY 144,204,460.07, up 405.83% from the same period last year[10]. - Net cash flow from operating activities rose significantly by 405.83% to 144,204,460.07 CNY, mainly due to reduced operating expenditures[19]. - Cash inflow from operating activities totaled $1.55 billion, a decrease of 4.94% compared to $1.63 billion in the previous period[52]. - Cash outflow from operating activities decreased to $1.41 billion from $1.60 billion, indicating better cost management[52]. - Investment activities generated a net cash flow of -$119.72 million, an improvement from -$547.51 million in the previous period[54]. - The net increase in cash and cash equivalents was $21.84 million, a turnaround from a decrease of $227.95 million in the previous period[55]. - The ending balance of cash and cash equivalents was $7.42 billion, slightly down from $7.55 billion in the previous period[55]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 30,070,185,491.17, an increase of 1.31% from the end of the previous year[10]. - Total current assets increased to ¥11,661,670,938.83 from ¥11,344,141,125.21, reflecting a growth of approximately 2.8%[37]. - Total non-current assets rose to ¥18,408,514,552.34 from ¥18,336,601,223.96, indicating an increase of approximately 0.4%[38]. - Total liabilities increased to ¥4,463,914,497.71 from ¥4,138,736,291.58, reflecting a growth of approximately 7.8%[40]. - Total liabilities increased to ¥5,536,893,616.67 from ¥5,227,180,203.91, reflecting a growth of 5.92%[42]. - Total equity attributable to shareholders of the parent company rose to ¥21,131,829,587.05 from ¥21,026,774,725.75, an increase of 0.50%[42]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,740[21]. - The top shareholder, Ye Xiaoping, holds 20.49% of shares, totaling 177,239,541 shares[23]. - The company has maintained a stable number of restricted shares at 171,687,044.00, with no new additions or removals during the reporting period[33]. Other Financial Metrics - Financial expenses increased by 37.34% to -21,920,357.75 CNY due to exchange rate fluctuations impacting foreign exchange gains[18]. - Other income surged by 198.25% to 15,369,745.78 CNY primarily from increased government subsidies received during the reporting period[18]. - Fair value changes in financial assets decreased by 92.77% to 12,753,272.78 CNY, attributed to declines in the stock prices of other non-current financial assets[18]. - Other comprehensive income after tax for the current period was -¥22,239,213.91, compared to -¥46,553,885.08 in the previous period[46]. Future Plans and Changes - The company plans to expand its market presence and enhance product offerings, although specific figures were not disclosed[34]. - The company plans to implement new accounting standards starting in 2024, which may impact financial reporting[56]. - The first quarter report was not audited, indicating preliminary financial results[56].

Financial Performance - Tigermed reported a revenue increase of 25% year-over-year, reaching CNY 3.5 billion in 2023[19]. - The company reported a net profit margin of 15%, up from 12% in the previous year[19]. - The company's operating revenue for 2023 was approximately ¥7.38 billion, representing a 4.21% increase compared to ¥7.09 billion in 2022[29]. - The net profit attributable to shareholders for 2023 was approximately ¥2.02 billion, a slight increase of 0.91% from ¥2.01 billion in 2022[29]. - The company reported quarterly revenues of ¥1.80 billion, ¥1.91 billion, ¥1.94 billion, and ¥1.73 billion for Q1, Q2, Q3, and Q4 respectively in 2023[31]. - The company’s main business revenue for 2023 was 7,289.11 million CNY, a year-on-year increase of 4.11% from 7,001.54 million CNY in the previous year[65]. - Total revenue for 2023 reached CNY 7,384,039,460.88, representing a year-on-year increase of 4.21% compared to CNY 7,085,471,468.87 in 2022[82]. Strategic Initiatives - The report outlines the company's strategic focus on expanding its market presence and enhancing its research capabilities through new product development[17]. - Tigermed plans to enter three new international markets, including Brazil, Mexico, and South Africa, by the end of 2024[20]. - The company is actively pursuing partnerships and collaborations to leverage resources and support its growth strategy[16]. - The company has established several wholly-owned subsidiaries to strengthen its operational framework and enhance service delivery[17]. - The company plans to enhance its integrated R&D service platform and expand its business units based on therapeutic areas or drug types to drive long-term growth[57]. Research and Development - The company is investing CNY 500 million in new product development and technology research in 2024[19]. - The company has accumulated over 3,500 clinical operation projects, including more than 700 Phase I clinical studies for new drugs in China and over 120 international multi-center clinical studies by the end of 2023[50]. - The company has witnessed a significant increase in R&D investment in the medical device sector, driven by new infrastructure, overseas revenue growth, and domestic substitution policies[46]. - The number of R&D personnel increased to 934 in 2023, a rise of 17.48% compared to 795 in 2022[92]. - The company has established integrated research service platforms for both pharmaceuticals and medical devices, enhancing collaboration and reducing communication costs in the R&D process[51]. Market Trends - The global pharmaceutical market is projected to grow from approximately USD 1.6 trillion in 2023 to USD 1.9 trillion by 2027, driven by increasing demand for innovative therapies[42]. - The CRO market size is expected to reach USD 102.65 billion by 2025, growing from USD 77.57 billion in 2022, reflecting a compound annual growth rate (CAGR) of approximately 9.5%[42]. - The number of clinical trials in China increased by 26.81% year-on-year, from 3,316 in 2022 to 4,205 in 2023[44]. - In 2023, 40 Class 1 new drugs were approved in China, marking a record high for the country[44]. Corporate Governance - The company emphasizes the accuracy and completeness of its financial report, with all board members present for the meeting[4]. - The report indicates a strong commitment to corporate governance and social responsibility initiatives[5]. - The company has implemented a business continuity management plan to mitigate risks from unforeseen events, although its effectiveness remains uncertain[115]. - The company has maintained independence from its controlling shareholder, ensuring no interference in decision-making or operations[131]. - The company emphasizes the importance of compliance with laws and regulations, as failure to adhere could lead to significant adverse effects on its business and financial status[118]. Employee and Talent Management - The company aims to increase its workforce by 20% to support its expansion and new projects[19]. - The company continues to focus on attracting, training, and retaining skilled personnel, as talent is crucial for maintaining service quality and meeting growth expectations[121]. - The total number of employees at the end of the reporting period is 9,701, with 2,042 in the parent company and 7,659 in major subsidiaries[160]. - The company has a total of 314 sales personnel, indicating a focused sales team[160]. Financial Policies and Dividends - The company plans to distribute a cash dividend of 5.68 CNY per 10 shares to all shareholders, based on a total of 864,948,570 shares[5]. - The cash dividend distribution represents 100% of the total distributable profit for the year, which amounts to approximately 8.77 billion RMB[165]. - The company has a robust cash dividend policy that aligns with its articles of association and shareholder resolutions, ensuring transparency and compliance[165]. Risks and Challenges - The company faces risks related to the potential decline in demand for biopharmaceutical research services, which could adversely affect its business and financial performance[116]. - Increased competition in the global clinical contract research organization market may pressure pricing and impact revenue and profitability[117]. - The company is exposed to foreign exchange risks, particularly with USD, which could negatively affect revenue growth and profit margins if the RMB appreciates significantly against the USD[123]. - The company acknowledges the potential for increased personnel costs as it competes for qualified talent in the CRO market[121]. Transparency and Reporting - The financial report will be made available on the designated website of the China Securities Regulatory Commission, ensuring transparency[12]. - The company disclosed a total of 4 periodic reports and 77 temporary announcements during the reporting period, ensuring transparency[129]. - The company has not engaged in any derivative investments or significant asset sales during the reporting period[109][111].

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 7,384.0 million, representing a 4.2% increase from RMB 7,085.5 million in 2022[2] - Adjusted net profit attributable to the company's owners increased by 7.2% to RMB 1,786.0 million from RMB 1,665.8 million in the previous year[2] - The company's net profit for the year decreased by 5.7% year-on-year from RMB 2,281.3 million to RMB 2,151.6 million, primarily due to increased sales costs and marketing expenses[47] - The profit attributable to the company's owners for 2023 was RMB 2,026.5 million, slightly up from RMB 2,016.1 million in 2022[52] - The company's gross profit was RMB 2,820.6 million, slightly up from RMB 2,785.4 million, with a gross margin decrease from 39.3% to 38.2%[35] - The company's total equity rose to RMB 24,453,562,000, an increase of 7.82% from RMB 22,681,028,000 in 2022[145] - The company's total assets as of December 31, 2023, amounted to RMB 25,542,006 thousand, up from RMB 23,716,941 thousand in 2022, reflecting a growth of 7.71%[134] Revenue Breakdown - Revenue from clinical trial-related services and laboratory services increased by 8.6% year-on-year, reaching RMB 3,215.9 million[19] - Revenue from the company's operations in China grew by 17.6% year-on-year, amounting to RMB 4,234.5 million, driven by its leading position in the clinical services market[19] - Revenue from clinical trial technical services was RMB 4,168,128,000, up from RMB 4,125,199,000, reflecting a growth of 1.04%[150] - Revenue from clinical trial related services and laboratory services increased significantly to RMB 3,215,911,000, a rise of 8.59% from RMB 2,960,272,000 in 2022[150] Assets and Liabilities - Total assets rose by 8.1% to RMB 29,680.7 million, compared to RMB 27,446.5 million in 2022[3] - The company's trade receivables and other receivables increased by 20.4% to RMB 1,428.2 million, driven by growth in business activities[59] - The company's contract assets rose by 18.4% to RMB 2,364.4 million, reflecting an increase in total contract amounts with clients[61] - The company's outstanding borrowings reached RMB 2,800.6 million as of December 31, 2023, with RMB 2,366.4 million classified as short-term borrowings[72] - The debt-to-equity ratio was reported at 11.5% as of December 31, 2023[73] Investments and Acquisitions - The company plans to enhance its end-to-end service capabilities and expand its global market share through mergers and acquisitions and by establishing business units based on therapeutic areas[11] - The company has committed additional capital of RMB 7.5 billion to invest in Hangzhou Taikun, a joint venture, as of December 31, 2023[77] - The company is a strategic investor in 170 innovative companies in the healthcare sector and a limited partner in 55 professional investment funds as of December 31, 2023[68] - The company plans to continue selective acquisitions and investments to achieve business growth, but failure to identify suitable targets or implement transactions successfully could adversely affect its financial performance[107] Research and Development - Research and development expenses increased by 11.5% year-on-year from RMB 234.6 million to RMB 261.6 million, attributed to a rise in the number of employees involved in R&D activities and their compensation[43] - The company has established integrated R&D service platforms for both pharmaceuticals and medical devices, covering the entire lifecycle of product development[85] - The company is investing heavily in R&D, with a budget allocation of 20 million USD for the development of new technologies[190] Market Trends and Outlook - The global pharmaceutical market is projected to reach approximately $1.6 trillion in 2023 and is expected to grow to $1.9 trillion by 2027, driven by aging populations and rising chronic non-communicable diseases[92] - The company anticipates further improvement in industry trends and the macro environment in the upcoming year[9] - Future outlook indicates a projected revenue growth of 15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[190] Compliance and Governance - The company has adopted the principles and provisions of the corporate governance code and has complied with its provisions during the reporting period[115] - The board approved a proposal to change the use of proceeds to better allocate financial resources and seize domestic market opportunities[120] - The company is committed to adhering to international financial reporting standards to ensure transparency and accuracy in financial reporting[188] Employee and Talent Management - The total number of employees increased from 9,455 as of June 30, 2023, and 9,233 as of December 31, 2022, to 9,701 as of December 31, 2023[38] - Attracting, training, motivating, and retaining skilled personnel is essential for the company's success, especially in the competitive pharmaceutical and medical device sectors[108] - The company acknowledges the limited supply of qualified personnel in the industry, necessitating competitive compensation and benefits to attract and retain talent[108] Risks and Challenges - The company faces risks from potential natural disasters, pandemics, and regulatory changes that could impact operations and financial performance[99][101] - Increased competition in the global clinical contract research organization market may pressure pricing and affect revenue and profitability[101] - The company faces risks related to obtaining and renewing necessary regulatory approvals, licenses, and certifications, which are critical for its operations[105]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年11月30日 狀態: 新提交 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2023年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 749,293,420 | RMB | | | 1 RMB | | 749,293,420 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 749,293,420 | RMB | | | 1 RMB | | 749,293,420 | | 2. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2023年11月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 749,293,420 RMB | | | 1 RMB | | 749,293,420 | | 增加 / 減少 (-) | | | | 0 | | | RMB | | 0 | | 本月底結存 | | | | 749,293,420 RMB | | | 1 RMB | | 749,293,420 | | 2. ...

Financial Performance - The company's revenue for Q3 2023 reached ¥1,939,627,566.42, representing a 7.05% increase year-over-year[2] - Net profit attributable to shareholders was ¥491,267,423.96, up 19.05% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses decreased by 3.75% to ¥404,950,398.38[2] - Total operating revenue for Q3 2023 reached ¥5,650,477,938.01, an increase of 4.52% compared to ¥5,406,018,843.59 in Q3 2022[16] - Gross profit for the period was ¥1,508,291,382.87, reflecting a gross margin of approximately 26.64%[16] - The company's net profit for Q3 2023 reached CNY 2,027,846,971.74, an increase of 14.4% compared to CNY 1,772,234,409.94 in Q3 2022[17] - Operating profit for the quarter was CNY 2,311,724,272.62, up from CNY 2,001,007,232.46 in the same period last year, reflecting a growth of 15.6%[17] - Basic and diluted earnings per share for the quarter were both CNY 2.17, compared to CNY 1.86 in the previous year, representing a growth of 16.7%[18] Assets and Liabilities - Total assets increased by 9.57% to ¥30,072,449,412.86 compared to the end of the previous year[2] - The company's total assets increased to ¥30,072,449,412.86, compared to ¥27,446,510,596.44 at the end of Q3 2022, marking a growth of 9.4%[15] - Total liabilities rose to ¥5,521,215,888.56, up from ¥4,765,479,654.95, indicating an increase of 15.87%[15] - The company's total equity reached ¥24,551,233,524.30, up from ¥22,681,030,941.49, marking a growth of 8.25%[15] Cash Flow - The company reported a net cash flow from operating activities of ¥672,644,481.56, down 18.51% year-to-date[2] - The cash inflow from operating activities was CNY 5,303,391,474.82, while cash outflow was CNY 4,630,746,993.26, resulting in a net cash inflow of CNY 672,644,481.56[19] - Net cash flow from operating activities for Q3 2023 was approximately ¥672.64 million, a decrease from ¥825.39 million in Q3 2022[20] - Net cash flow from investing activities decreased by 33.94% to -1,592,504,848.56 CNY compared to the same period last year[7] - The net cash flow from investing activities was -¥1.59 billion, improving from -¥2.41 billion year-over-year[20] - Total cash inflow from financing activities increased to approximately ¥3.06 billion, compared to ¥2.95 billion in the previous year[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 56,356, with the largest shareholder, Ye Xiaoping, holding 20.32% of shares, equating to 177,239,541 shares[8] - The top ten shareholders collectively hold significant stakes, with HKSCC NOMINEES LIMITED owning 14.11% (123,119,379 shares) and Hong Kong Central Clearing Limited holding 6.12% (53,420,466 shares)[8] - The company reported a total of 181,907,044 shares under lock-up agreements at the end of the reporting period, with 4,125,000 shares released during the current period[12] - The company is actively managing its shareholder structure, with notable actions taken by major shareholders, including share pledges and lock-up agreements[12] Investments and R&D - The company plans to expand its investment in joint ventures, leading to a 61.05% increase in long-term equity investments to ¥2,898,551,203.83[5] - Research and development expenses for the period were ¥195,343,150.53, compared to ¥171,055,447.09 in the previous year, indicating an increase of 14.2%[16] Other Financial Metrics - The company received government subsidies amounting to ¥10,521,363.70 year-to-date, which contributed to its financial performance[3] - The company's cash and cash equivalents amounted to 7,417,101,360.17 CNY, a decrease from 7,858,139,864.36 CNY at the beginning of the year[13] - Accounts receivable increased to 1,176,009,099.35 CNY from 1,027,789,335.66 CNY, indicating a growth in sales or credit terms extended to customers[13] - The company's cash and cash equivalents were reported at ¥11,465,404,979.73, a slight increase from ¥11,107,248,144.90 year-over-year[15] - Inventory levels increased to ¥27,238,796.09, compared to ¥22,204,440.32 in the previous year, representing a growth of 22.73%[15] Changes and Standards - The company did not undergo an audit for the Q3 report[20] - The company implemented new accounting standards starting in 2023, affecting the financial statements[20]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2023年第三季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為杭州泰格醫藥科技股份有限公司（「本公司」，連同其子公司統稱「本集團」） 截至2023年9月30日止九個月第三季度報告。本公告及隨附的財務報表最初以中 文編製，並以中英文版本刊登。如中英文版本有任何歧義或衝突，概以中文版本 為準。 謹請本公司股東及公眾投資者注意，隨附財務報表乃根據中國企業會計準則編製 且未經審計。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 香港，2023年10月27日 於本公告日期，本公司執行董事為葉小平博士、曹曉春女 ...

杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第三次会议于 2023年10月27日在杭州市滨江区聚工路19号8幢19层会议室举行，本次会议以现场与通讯 表决相结合的方式召开。会议通知已于2023年10月13日以电话、电子邮件方式向全体董事 发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次会议的 召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 证券代码：300347 证券简称：泰格医药 公告编码（2023）032 号 杭州泰格医药科技股份有限公司 第五届董事会第三次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 具体内容详见中国证监会创业板指定信息披露网站同期披露的《公司2023年第三季度 报告》。 表决结果：同意7票，反对0票，弃权0票。 特此公告。 一、审议并通过《关于公司2023年第三季度报告的议案》。 杭州泰格医药科技股份有限公司董事会 二〇二三年十月二十八日 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347) 董事會會議召開日期 杭州泰格醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，將於二零二三年十月二十七日（星期五）舉行董事會會議，藉以（其中包括）審 議及批准本公司及其附屬公司截至二零二三年九月三十日止九個月的第三季度報 告及╱或其他議題（如適用）。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 董事長 香港，二零二三年十月十六日 於本公告日期，執行董事為葉小平博士、曹曉春女士、吳灝先生及聞增玉先生； 獨立非執行董事為楊波博士、廖啟宇先生及袁華剛先生。 ...